Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast

RICHMOND, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and year-end 2007 financial results on Tuesday, February 5, 2008, after the market closes. The press release will be followed by a conference call at 2:00 p.m. PT, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-545-1489 for domestic callers and 719-325-4844 for international callers. The passcode for the call is 4452025. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 5:00 p.m. PT on February 5, 2008 to 11:59 p.m. PT on February 12, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 4452025.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
2. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
3. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
4. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
5. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
6. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
7. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... assessment of organotypic 3D cell culture models, has launched a 14 Day ... their patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing ...
(Date:10/13/2015)... 13, 2015 " Microbiology Culture Market ... - 2023 " , the global microbiology culture ... to reach US$7.59 bn by 2023, expanding at a CAGR of ... " Microbiology Culture Market - Global Industry Analysis, Size, ... , the global microbiology culture market was valued at US$4.51 ...
(Date:10/13/2015)... October 13, 2015      Q ... company, has entered into a strategic relationship with Wombat ... and Paris, France based strategic ... --> This collaborative arrangement gives Q BioMed ... advisory team as well as long established pharmaceutical industry ...
(Date:10/13/2015)... ... 13, 2015 , ... Exotic Automation & Supply , ... components, is opening its latest Parker Store retail location in Ann, Arbor, MI. ... major expansion in Metropolitan Detroit in less than a year. The Ann Arbor ...
Breaking Biology Technology:
(Date:10/8/2015)... , October 8, 2015 ... or the "Company"), a biometric authentication company focused ... of the Wocket® smart wallet announces that revenues ... were approximately $410,000 compared with $113,00 for the ... the 9 months ended September 30, 2015 were ...
(Date:10/5/2015)... 2015 ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... ) releases the following market ... ), a biometric authentication company focused on the growing ... ( ) releases the following market ...
(Date:9/30/2015)... YORK , Sept. 30, 2015  The global glucose ... billion for 2015. So says a new report on the ... diabetes management segment dominate the market, followed by continuous glucose ... publisher. Kalorama reports on the market for these products in its ... ...
Breaking Biology News(10 mins):